The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBYOT.L Regulatory News (BYOT)

  • There is currently no data for BYOT

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Grant Award

7 Sep 2020 07:00

RNS Number : 1222Y
Byotrol PLC
07 September 2020
 

 

 

Byotrol Plc

("Byotrol" or the "Group")

 

Award of £350k grant to investigate anti-viral properties of seaweed

 

 

 

 

Byotrol plc (AIM:BYOT), the specialist infection prevention and control company, is pleased to announce that it has secured a significant grant from Innovate UK to further investigate the anti-viral properties of certain common forms of seaweed.

 

The total award is £350k over 16 months, of which £108k will be paid to Byotrol's academic partner, the Molecular Virology Research Group at the University of Liverpool, led by Professor James Stewart. The grant is specifically for research into seaweeds in sanitising products, but we believe the resulting discoveries will have significance outside of Byotrol's core markets, including potentially animal feedstuffs.

 

This grant award will help Byotrol build further on its research and development programme into developing biocides from sustainable sources. This programme, which Byotrol has been exploring for many years has demonstrated high potency anti-viral action from extracts from commonly-occurring seaweeds, the results of which have already supported a new patent filing by the Group. Byotrol expects to file further patents as the programme develops.

 

 

 

 

Trevor Francis, Chief Technology Officer of Byotrol plc commented:

 

We are delighted that Innovate UK is supporting our research into the anti-viral properties of seaweeds and we are very pleased to be working on this project with Professor James Stewart's excellent team at the University of Liverpool. It is a very exciting area of development for Byotrol.

 

 

 

 

Enquiries:

 

Byotrol plc

Trevor Francis - Chief Technology Officer

David Traynor - Chief Executive Officer

Nic Hellyer - Chief Financial Officer 01925 742 000

 

finnCap

Geoff Nash/Kate Bannatyne - Corporate Finance 020 7220 0500

Richard Chambers - ECM

 

Flagstaff Strategic and Investor Communications

Tim Thompson/Andrea Seymour/Fergus Mellon +44 (0)207 129 1474

byotrol@flagstaffcomms.com

 

 

 

This announcement is released by Byotrol plc and, prior to publication, the information contained herein was deemed to constitute inside information under the Market Abuse Regulations (EU) No. 596/2014. Such information is disclosed in accordance with the Company's obligations under Article 17 of MAR.

 

 

 

Notes to Editors:

 

Byotrol plc (BYOT.L), quoted on AIM, is a specialist infection prevention and control company, operating globally in the Healthcare, Industrial, Food and Consumer sectors, providing low toxicity products with a broad-based and targeted efficacy across all microbial classes; bacteria, viruses (including coronavirus), fungi, moulds, mycobacteria and algae.

 

Byotrol's products can be used stand-alone or as ingredients within existing products, where they can significantly improve their performance, especially in personal hygiene, domestic and industrial disinfection, odour control, food production and food management.

 

Byotrol develops and commercialises technologies that create easier, safer and cleaner lives for everyone.

 

For more information, please go to byotrol.co.uk

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCKKQBQQBKDBCK
Date   Source Headline
1st Nov 202111:36 amRNSTotal Voting Rights
1st Nov 202111:20 amRNSHolding(s) in Company
28th Oct 202111:40 amRNSExercise of Options & Total Voting Rights
20th Oct 20214:46 pmRNSResult of AGM
1st Oct 20217:00 amRNSSale of Byotrol24 in the Americas
27th Sep 20214:36 pmRNSPosting of Annual Report & Accounts/Notice of AGM
1st Sep 20217:00 amRNSInvestor Presentation
20th Aug 202110:01 amRNSHolding(s) in Company
19th Aug 20217:00 amRNSFinal Results
27th Jul 20217:00 amRNSNotice of Results
21st Jun 20217:00 amRNSAlcohol-free Hand Sanitisers Backed by TIGGR
28th Apr 20219:47 amRNSExercise of Options & Total Voting Rights
27th Apr 20217:00 amRNSHolding(s) in Company
22nd Apr 20212:05 pmRNSSecond Price Monitoring Extn
22nd Apr 20212:00 pmRNSPrice Monitoring Extension
22nd Apr 20217:00 amRNSTrading Update
16th Apr 20214:40 pmRNSHolding(s) in Company
26th Feb 20217:00 amRNSTest Protocol for Testing Anti-Viral Efficacy
21st Jan 202110:30 amRNSExercise of Options & Total Voting Rights
8th Jan 20219:36 amRNSCapital reduction
21st Dec 20208:26 amRNSHolding(s) in Company
7th Dec 20207:00 amRNSInterim Results
13th Nov 202011:30 amRNSResult of AGM
13th Nov 20207:00 amRNSAGM Statement
6th Nov 202011:27 amRNSAnnual General Meeting – update on arrangements
20th Oct 20201:42 pmRNSPosting of circular & notice of AGM
14th Oct 20204:30 pmRNSExercise of Options & Total Voting Rights
13th Oct 202011:09 amRNSPUBLICATION OF AUDITED RESULTS
25th Sep 20207:00 amRNSDirector Dealing
25th Sep 20207:00 amRNSInvestor Presentation
24th Sep 20207:00 amRNSPreliminary Results
7th Sep 20207:00 amRNSGrant Award
27th Aug 20208:07 amRNSHolding(s) in Company
20th Aug 20208:10 amRNSHolding(s) in Company
18th Aug 20205:01 pmRNSHolding(s) in Company
18th Aug 20204:42 pmRNSSecond Price Monitoring Extn
18th Aug 20204:36 pmRNSPrice Monitoring Extension
17th Aug 20209:05 amRNSSecond Price Monitoring Extn
17th Aug 20209:00 amRNSPrice Monitoring Extension
3rd Aug 20207:00 amRNSTrading Update
16th Jul 20202:40 pmRNSHolding(s) in Company
3rd Jul 20207:00 amRNSExercise of Options and Total Voting Rights
29th Jun 20204:29 pmRNSHolding(s) in Company
19th May 202012:08 pmRNSHolding(s) in Company
14th May 20207:00 amRNSLicense Agreements and Update on Trading
27th Apr 20207:30 amRNSTrading Update
22nd Apr 20204:41 pmRNSSecond Price Monitoring Extn
22nd Apr 20204:36 pmRNSPrice Monitoring Extension
8th Apr 20207:00 amRNSHolding(s) in Company
6th Apr 202011:26 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.